Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 6/20 | 0.41 |
| ▸ | RXRA | P19793 | 9/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.34 |
| ▸ | HNF4A | P41235 | 3/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 2/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072959 | 0.92 | RARG (0.41) | RARGRXRAPPARGNR1H3CYP26A1 | |
| SCHEMBL3062988 | 0.91 | RXRA (0.36) | RARGRXRAPPARGNR1H3CYP26A1 | |
| SCHEMBL3076551 | 0.90 | RXRA (0.40) | RARGRXRAPPARGNR1H3CYP26A1 | |
| SCHEMBL11971729 | 0.88 | RXRA (0.36) | RARGRXRAPPARGNR1H3CYP26A1 | |
| SCHEMBL1990930 | 0.87 | CYP26A1 (0.45) | RARGRXRAPPARGNR1H3CYP26A1 | |
| SCHEMBL3460491 | 0.86 | RARG (0.35) | RARGRXRACYP26A1CYP3A4CYP26B1 | |
| SCHEMBL3074772 | 0.85 | RXRA (0.40) | RARGRXRAPPARGNR1H3CYP26A1 | |
| SCHEMBL3065406 | 0.82 | RARA (0.41) | RARGRXRAPPARGNR1H3CYP26A1 | |
| SCHEMBL3070732 | 0.82 | RXRA (0.37) | RARGRXRAPPARGNR1H3CYP26A1 | |
| SCHEMBL3070788 | 0.82 | RXRA (0.35) | RXRAPPARGNR1H3CYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767650-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-03 | — | — | US | claimed |
| EP-1694627-B1 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2009-05-27 | — | — | EP | claimed |
| US-20070117761-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-24 | — | — | US | claimed |
| EP-1694627-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-30 | — | — | EP | claimed |
| WO-2005056510-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | claimed |
| US-8765805-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-07-01 | — | — | US | disclosed |
| US-20120214869-A1 | NOVEL LIGAND ACTIVATORS OF THE RAR RECEPTORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-08-23 | — | — | US | disclosed |
| US-8188106-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100273883-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-28 | — | — | US | disclosed |
| US-7767650-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-03 | — | — | US | disclosed |
| EP-1694627-B1 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2009-05-27 | — | — | EP | disclosed |
| US-20070117761-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-24 | — | — | US | disclosed |
| EP-1694627-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005056510-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117761-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | RARA, RARB, RARG | RARG 3/4885RXRA 4/4885PPARG 7/4885 |
| US-20100273883-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | RARA, RARB, RARG | RARG 3/4885RXRA 4/4885PPARG 7/4885 |
| US-20120214869-A1 | NOVEL LIGAND ACTIVATORS OF THE RAR RECEPTORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | RARA, RARB, RARG | RARG 3/4885RXRA 4/4885PPARG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.